November 14, 2018 09:52 AM EST

Eluded by clear success in esophageal carcinoma, Merck touts subgroup OS win for Keytruda

Amber Tong

Merck didn’t exactly get the clean sweep it wanted to show Keytruda beats out standard second-line therapy in esophageal or esophagogastric junction carcinoma — but the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eluded by clear success in esophageal carcinoma, Merck touts subgroup OS win for Keytruda

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Elud­ed by clear suc­cess in esophageal car­ci­no­ma, Mer­ck touts sub­group OS win for Keytru­da

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Eluded by clear success in esophageal carcinoma, Merck touts subgroup OS win for Keytruda

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial